March 15, 2022 Ryvu Therapeutics S.A. Annual Report 2021
Read More
December 30, 2021 Ryvu Therapeutics to receive from Menarini Group a development milestone based on an amended global License Agreement
Read More
December 20, 2021 Ryvu Therapeutics receives approval to conduct Phase I/II study of RVU120 (SEL120) in patients with relapsed/refractory metastatic or advanced solid tumors in Spain
Read More
December 17, 2021 Change order to the statement of work
Read More
December 14, 2021 Galapagos NV exercises its exclusive option to license program with therapeutic potential in inflammatory diseases
Read More
December 13, 2021 Ryvu Therapeutics Presents Clinical and Translational Data Updates at the 63rd American Society of Hematology (ASH) Annual Meeting and the 44th San Antonio Breast Cancer Symposium
Read More
November 19, 2021 Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program – Article 19 of MAR
Read More
November 10, 2021 Ryvu Therapeutics S.A. Q3 2021 Financial Report
Read More
November 9, 2021 Ryvu Therapeutics to highlight HPK1 and STING Programs at the upcoming SITC Conference
Read More
November 4, 2021 Ryvu’s partner Menarini Group receives FDA Orphan Drug Designation for SEL24 (MEN1703) for the Treatment of Acute Myeloid Leukemia
Read More
November 4, 2021 Clinical and Translational Data from RVU120 and SEL24(MEN1703) programs to be presented at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition and the 44th Annual San Antonio Breast Cancer Symposium (SABCS)
Read More
September 24, 2021 Filing a lawsuit against Mota-Engil Central Europe S.A. in connection with construction of the Research and Development Center
Read More
September 8, 2021 Ryvu Therapeutics H1 2021 Financial Report
Read More
August 25, 2021 First Patient Dosed in Phase I/II Study of RVU120 (SEL120) in Patients with Relapsed/Refractory Metastatic or Advanced Solid Tumors
Read More
August 25, 2021 Resignation of the Member of the Management Board
Read More
August 18, 2021 Notification from Aviva Otwarty Fundusz Emerytalny Aviva Santander on exceeding the threshold of 5% of the total number of votes in the Company
Read More
August 13, 2021 Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program – Article 19 of MAR
Read More
July 21, 2021 Notification from person discharging managerial responsibilities in the Company – Article 19 of MAR
Read More
July 14, 2021 FDA lifts partial clinical hold on RVU120 (SEL120) Phase Ib study in acute myeloid leukemia and myelodysplastic syndrome
Read More
July 13, 2021 Notifications from persons discharging managerial responsibilities in the Company – Article 19 of MAR
Read More
Posts navigation
